Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine.

Trial Profile

Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Rimegepant (Primary) ; Sumatriptan
  • Indications Migraine
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Nov 2017 Primary endpoint (Pain Freedom (from migraine pain)) has been met according to a Biohaven Pharmaceutical Holding Company.
    • 12 Aug 2013 Results published in Cephalalgia.
    • 30 Jun 2013 Results presented at the 2013 International Headache Congress .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top